Ascentage Pharma Group International ( (HK:6855) ) has shared an announcement.

Ascentage Pharma reported a 29.3% year-on-year rise in interim revenue to RMB302.2 million for the six months ended June 30, 2026, driven by a 32.6% increase in product sales, notably Lisaftoclax. Operating expenses climbed 36.1% to RMB1,042.7 million on higher research and development and marketing spend, widening the net loss to RMB817.0 million and reducing cash and bank balances to RMB1,895.6 million as the company invested heavily in global clinical programs.

Operationally, the company strengthened its leadership by appointing a Chief Business Officer to lead global business development and a Chief Commercial Officer to drive commercialization outside China, particularly in the U.S. It also removed the “B” marker from its Hong Kong stock short name after meeting enhanced market capitalization and revenue thresholds, underscoring its maturation as a listed biotech, while advancing its pipeline with APG-3288, a BTK-targeted protein degrader now in Phase I trials for relapsed or refractory hematologic malignancies following regulatory clearances in both the U.S. and China.